EFRAIN MENDEZ: Open Payments
NPI 1871640847 · KISSIMMEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$429 in 21 payments from 9 companies in 2025. Trend: 2023 $313 · 2024 $330 · 2025 $429
Food & beverage: $429
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
Products named: REXULTI, VRAYLAR, CAPLYTA, HETLIOZ, TRINTELLIX, INGREZZA, ARISTADA.
Industry payments across FL — which companies pay providers there.
